On March 15, 2023 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that the company, along with its partners, will present five new abstracts at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting from April 14-19, 2023 (Press release, Jazz Pharmaceuticals, MAR 15, 2023, View Source [SID1234628848]). Research findings to be presented include data from company-sponsored and collaborative trials studying Zepzelca (lurbinectedin), zanidatamab and JZP898.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The data Jazz and our partners are presenting at AACR (Free AACR Whitepaper) this year demonstrate our commitment to advancing the next generation of oncology care, including our ongoing research for lurbinectedin," said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals. "Over the last year, Jazz has added promising new immuno-oncology and targeted therapy candidates to our pipeline – including zanidatamab, a novel late-stage HER2-targeted bispecific antibody – and progressed ongoing development programs with the goal of improving standards of care across multiple cancer types with significant unmet need and poor outcomes."
Data highlights at the AACR (Free AACR Whitepaper) Annual Meeting include:
A poster presentation evaluating the role of SLFN11 expression in predicting response to lurbinectedin, a DNA damaging agent, in human small cell lung cancer (SCLC) cell lines and in vivo models. Results demonstrate that efficacy may be correlated to SLFN11 protein expression, consistent with the RNA level association.1
A poster presentation featuring data identifying MCL1 as a specific lurbinectedin target and demonstrating anti-tumor activity of lurbinectedin in combination with a specific BCL2 inhibitor and with a specific BCL2L1 inhibitor in in vivo and in vitro models.2
A poster presentation titled "ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers."
The AACR (Free AACR Whitepaper) abstracts are available at: View Source!/10828/
The full list of Jazz-supported presentations at the 2023 AACR (Free AACR Whitepaper) Annual Meeting are:
Zepzelca (lurbinectedin) Presentations
Presentation Title
Author
Presentation Details
High SLFN11 expression correlates with sensitivity to lurbinectedin in small cell lung cancer (SCLC) models
Gupta A., et al.
Type: Poster
Session: Biomarkers of Therapeutic Benefit 2
Date: Monday, April 17, 2023, 9:00 AM – 12:30 PM
Abstract number: 2145
Lurbinectedin exhibits combinatorial activity with BCL2/BCL2L1 inhibitors in vitro and in vivo by modulation of MCL1 expression
Vaidya K.S., et al.
Type: Poster
Session: Cell Death Pathways/ Molecular Classifications of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes
Date: Wednesday, April 19, 2023, 9:00 AM – 12:30 PM
Abstract number: 6155
Lurbinectedin shows potent activity in all four molecular subtypes of small cell lung cancer (SCLC) and POU2F3 and SLFN11 are biomarkers for a better response
Diez M.M., et al.
Type: Poster
Session: DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents
Date: Wednesday, April 19, 2023, 9:00 AM – 12:30 PM
Abstract number: 6247
Zanidatamab Presentation*
Presentation Title
Author
Presentation Details
ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers
Shpektor D., et al.
Type: Poster
Session: Phase I Clinical Trials 2
Date: Tuesday, April 18, 2023, 1:30 PM – 5:00 PM
Abstract number: CT278
*Clinical trial abstract texts are embargoed until noon ET on April 14, 2023.
JZP898 Presentation
Presentation Title
Author
Presentation Details
WTX-613, (JZP898) a selectively activated IFNα INDUKINE molecule, reprograms the tumor microenvironment and generates robust anti-tumor immunity as a monotherapy and in combination with checkpoint inhibitors
Nirschl CJ, et al.
Type: Poster
Session: Immunomodulatory Agents and Interventions 1
Date: Monday April 17, 2023 9:00 AM – 12:30 PM
Abstract number: 1817